top of page

therapeutic areas

  • Rare and orphan diseases: hemophilia, hereditary angioedema, Fabry, Gaucher, CLL, pulmonary hypertension, hereditary hyper-cholesterolemia, multiple scleroses, Pompe, etc.

  • Oncology products (traditional and biologic)

  • Rheumatoid arthritis, Lupus, Psoriatic  arthritis (traditional and biologic)

  • Anti-infective/Anti-viral agents (Anthelmintics, Antibacterial agents, Antibiotics, Antimicotics, HIV, etc.)

  • Immunosuppressive agents

  • Antidiabetic agents (oral, injectables, insulins, full coverage)

  • Antihistamines

  • Anticoagulants, platelet aggregation inhibitors, thrombolytic agents, etc.

  • Vaccines

  • Nuclear medicine

  • Contraceptives (Contraceptives, intracervical devices, intrauterine devices, intravaginal, sub-dermal implant) 

  • Bronchodilators

  • Bone diseases (osteoporoses, etc.)

  • Cardiovascular drugs (Angiotensin converting enzyme inhibitors, Calcium antagonists, Hypotensive agents, Vasodilating agents, etc)

  • Central nervous system drugs (Analgesics, Anticonvulsants, Antidepressants, Central nervous system depressants, Anxiolytics, Antimanic agents, Alzheimer products, Multiple scleroses, etc.)

  • Corticoids

  • Dermatology products, psoriasis

  • Gastrointestinal drugs (Antacids, Antidiarrhea agents, Cathartics and laxatives, Anti-emetics)

  • Hormones (Androgens, Contraceptives, Estrogens, Estrogens conjugated, Gonadotropins)

  • Nutrotherapic products

  • Dietary supplements (adults, pediatrics)

  • Infant milk formulas

  • Ophthalmic (monoclonal, etc.)

  • Pain management

  • Sexual dysfunction 

  • Vitamins

case studies
angoio02_edited.jpg
Rare diseases: Hereditary Angioedema
Challenge
  • Situation diagnosis for the Hereditary Angioedema market in Argentina: Incidence, Treatment and Up-take of the new product.  Treatment costs.  Approval circuit within institutions.  Incorporation circuit of new product within PAMI, IOMA and  Pre-paid Healthcare System
Actions
  • Exploratory qualitative study, interviewing specialists (allergies and immunology) and auditors within target institutions.
Result
  • Able to plan actions to access target institutions based on the positioning of the new product according to cost-benefit assessment in crisis prevention.
Rare Disease: Chronic immune deficiency
Challenge
  • Situation diagnosis for the Chronic immune deficiency market: patient workload, referral circuit, diagnosis and indications, brand positioning
Actions
  • Exploratory qualitative study, interviewing Hematologists, Immunologists and Neurologists.
Result
  • Able to identify specific indications treated with gamma globulin by different specialists and patient workloads;  competitive capacity of the product within the market.
Rare Disease: Hemophilia
Challenge
  • Identification of business opportunities within the Hemophilia market:  market sizing, patient flow and treatment pathway.  Coverage and access to treatment.
Actions
  • Qualitative study with quantitative validation, interviewing hematologists – KOL’s, High Prescribers, auditing Doctors.  Type A Hemophilia patients and caregivers.
Result
  • Able to evaluate with precision the sales potential of the product during the different stages of the disease.  Also able to size the strategic opportunity for secondary prevention.
bottom of page